08:02 AM EDT, 03/19/2026 (MT Newswires) -- Pfizer ( PFE ) said Thursday the investigational combination of Talzenna and Xtandi met the primary endpoint of a phase 3 trial, "significantly" improving radiographic progression-free survival of patients with homologous recombination repair gene-mutated metastatic castration-sensitive prostate cancer, compared with placebo plus Xtandi.

During an interim analysis, results also showed a trend toward improved overall survival, a secondary endpoint, the company said.

Benefits were also observed in other secondary endpoints, including overall response rate and duration of response, the company said.

The safety profile of the combination treatment was consistent with the known safety profile of each medicine, with no new safety concerns detected, Pfizer ( PFE ) said.